



CCM DUOPHARMA BIOTECH BERHAD (524271-W)

(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME  
FOR THE PERIOD ENDED 31 MARCH 2015

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 3/31/2015 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 3/31/2014 RM'000	CURRENT YEAR TO DATE 3/31/2015 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 3/31/2014 RM'000
Revenue	45,599	40,495	45,599	40,495
Cost of Sales	(22,050)	(20,748)	(22,050)	(20,748)
<b>Gross Profit</b>	<b>23,549</b>	<b>19,747</b>	<b>23,549</b>	<b>19,747</b>
Other operating income	-	34	-	34
Distribution costs	(4,333)	(4,805)	(4,333)	(4,805)
Administration expenses	(3,915)	(3,712)	(3,915)	(3,712)
Other operating expenses	(3,141)	(92)	(3,141)	(92)
<b>Profit from operations</b>	<b>12,160</b>	<b>11,172</b>	<b>12,160</b>	<b>11,172</b>
Finance income	79	74	79	74
Finance costs	(41)	(71)	(41)	(71)
<b>Profit before taxation</b>	<b>12,198</b>	<b>11,175</b>	<b>12,198</b>	<b>11,175</b>
Taxation	(3,229)	(2,810)	(3,229)	(2,810)
<b>Profit after tax for the period</b>	<b>8,969</b>	<b>8,365</b>	<b>8,969</b>	<b>8,365</b>
<b>Other comprehensive income</b>	-	-	-	-
<b>Total other comprehensive income for the period</b>	<b>8,969</b>	<b>8,365</b>	<b>8,969</b>	<b>8,365</b>
<b>Profit attributable to:</b>				
Shareholders of the Company	8,969	8,365	8,969	8,365
Minority interest	-	-	-	-
	<b>8,969</b>	<b>8,365</b>	<b>8,969</b>	<b>8,365</b>
<b>Total other comprehensive income attributable to:</b>				
Shareholders of the Company	8,969	8,365	8,969	8,365
Minority interest	-	-	-	-
	<b>8,969</b>	<b>8,365</b>	<b>8,969</b>	<b>8,365</b>
Earnings per share (sen)				
Basic (based on weighted average)	6.43	6.03	6.43	6.03
Diluted (based on weighted average)	6.43	6.03	6.43	6.03

- The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2014 and the accompanying explanatory notes attached to the interim financial statements.



CCM DUOPHARMA BIOTECH BERHAD (524271-W)

(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION  
AS AT 31 MARCH 2015

	AS AT 31/3/2015 RM'000	AS AT 31/12/2014 RM'000
<b>ASSETS</b>		
Property, Plant and Equipment	104,600	101,060
Investment properties	11,500	11,500
Intangible assets	3,586	3,063
<b>Total non-current assets</b>	<u>119,686</u>	<u>115,623</u>
Inventories	45,736	44,644
Trade & Other Receivables	40,254	41,171
Amount Due From Related Company	3,022	2,736
Cash & Cash Equivalents	30,485	18,303
<b>Total current assets</b>	<u>119,497</u>	<u>106,854</u>
<b>Total Assets</b>	<u><u>239,183</u></u>	<u><u>222,477</u></u>
<b>EQUITY</b>		
Share Capital	69,739	69,739
Reserves	14,306	13,720
Retained earnings	120,718	111,749
Treasury Shares	-	(1,578)
<b>Total Equity</b>	<u>204,763</u>	<u>193,630</u>
<b>LIABILITIES</b>		
Deferred Tax Liability	5,499	5,500
Borrowings	-	-
<b>Total non-current liabilities</b>	<u>5,499</u>	<u>5,500</u>
Trade & Other Payables	21,215	15,259
Amount due to related company	4,315	5,607
Provision	674	758
Taxation	2,717	1,723
<b>Total current liabilities</b>	<u>28,921</u>	<u>23,347</u>
<b>Total Liabilities</b>	<u><u>34,420</u></u>	<u><u>28,847</u></u>
<b>Total Equity &amp; Liabilities</b>	<u><u>239,183</u></u>	<u><u>222,477</u></u>
<b>Net assets per share (RM)</b>	<b>1.47</b>	<b>1.39</b>

(The Condensed Consolidated Balance Sheet should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2014 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)  
(Incorporated in Malaysia)  
**UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT**  
**FOR THE PERIOD ENDED 31 MARCH 2015**

	31 March 2015 RM '000	31 March 2014 RM '000
<b>Cash flows from operating activities</b>		
Profit before taxation	12,198	11,175
Adjustments for:		
Depreciation of property, plant and equipment	2,139	2,069
Interest income	(79)	(23)
Finance costs	41	71
<i>Operating profit before changes in working capital</i>	14,299	13,292
Change in inventories	(1,092)	(16,630)
Change in receivables, deposits and prepayments	401	(941)
Change in payables and accruals	4,801	9,986
<i>Cash generated from operations</i>	18,409	5,707
Finance costs paid	(41)	(71)
Interest income	79	23
Income tax paid	(2,234)	(2,170)
Net cash generated from operating activities	16,213	3,489
<b>Cash flows from investing activities</b>		
Acquisition of property, plant and equipment	(6,203)	(4,340)
Cost associated to conversion of land to industrial status		
Proceed from disposal of property, plant and equipment		
Proceed from issuance of shares	2,172	
Net cash used in investing activities	(4,031)	(4,340)
<b>Cash flows from financing activities</b>		
Net cash used in financing activities	-	-
Net decrease in cash and cash equivalents	12,182	(851)
Cash and cash equivalents at 1 January	18,303	18,879
Cash and cash equivalents as at 31 March	30,485	18,028

(i) Cash and cash equivalents comprise:

	<u>RM '000</u>	<u>RM '000</u>
Cash and bank balances	23,310	5,258
Deposits placed with licensed financial institutions	7,175	12,770
	30,485	18,028

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2014 and the accompanying explanatory notes attached to the interim financial statements.)